Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (ATXS)
NASDAQ:ATXS
Holding ATXS?
Track your performance easily
ATXS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.41 - $16.90
Previous Close$9.58
Volume19.34K
Average Volume (3M)317.83K
Market Cap
$537.02M
Enterprise Value$211.59M
Total Cash (Recent Filing)$344.28M
Total Debt (Recent Filing)$5.64M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Mar 06, 2025EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding56,434,219
10 Day Avg. Volume264,659
30 Day Avg. Volume317,834
Standard Deviation0.30
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.20
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.38
Forecast
1Y Price Target
$24.83Price Target Upside165.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Astria Therapeutics News
PremiumCompany Announcements
Astria Therapeutics Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is ATXS a Buy, Before Earnings?
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATXS FAQ
What was Astria Therapeutics’s price range in the past 12 months?
Astria Therapeutics lowest stock price was $4.41 and its highest was $16.90 in the past 12 months.
What is Astria Therapeutics’s market cap?
Currently, no data Available
When is Astria Therapeutics’s upcoming earnings report date?
Astria Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 105 days.
How were Astria Therapeutics’s earnings last quarter?
Astria Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.422 by $0.002.
Is Astria Therapeutics overvalued?
According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued.
Does Astria Therapeutics pay dividends?
Astria Therapeutics does not currently pay dividends.
What is Astria Therapeutics’s EPS estimate?
Astria Therapeutics’s EPS estimate is -$0.45.
How many shares outstanding does Astria Therapeutics have?
Astria Therapeutics has 56,434,220 shares outstanding.
What happened to Astria Therapeutics’s price movement after its last earnings report?
Astria Therapeutics reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.422. Following the earnings report the stock price went down -4.901%.
Which hedge fund is a major shareholder of Astria Therapeutics?
Among the largest hedge funds holding Astria Therapeutics’s share is Perceptive Advisors LLC. It holds Astria Therapeutics’s shares valued at 71M.
---
Astria Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.83 (165.56% Upside)
$24.83 (165.56% Upside)
Blogger Sentiment
Bearish
ATXS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 63.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
110.54%
12-Months-Change
Fundamentals
Return on Equity
-38.03%
Trailing 12-Months
Asset Growth
86.55%
Trailing 12-Months
Company Description
Astria Therapeutics
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
---
ATXS Company Deck
---
ATXS Earnings Call
Q3 2023
0:00 / 0:00
---
ATXS Stock 12 Month Forecast
Average Price Target
$24.83
▲(165.56% Upside)
Technical Analysis
Seres Therapeutics
―
Fate Therapeutics
―
Voyager Therapeutics
―
Alaunos Therapeutics
―
Best Analysts Covering ATXS
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+21.51%
reiterated a buy rating 3 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +21.51% per trade.
---